Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of CAStem cell injection for acute graft-versus-host disease
ChiCTR2300077942Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CAStem cells in Acute Graft-Versus-Host Disease (aGvHD) (3 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Overall response rate. Started Nov 2023; status: recruiting.
02
Drugs
CAStem cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ChiCTR2300077942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077942.